OTLK Company Profile and Key Details

Outlook Therapeutics, Inc. (NASDAQ:OTLK) closed at $0.47 USD, gaining $0.07 (17.42%) from the previous close of $0.40. The stock is currently mid-range between its 52-week high and low $0.16 and $3.39. With a market capitalization of about $19.33 million, Outlook Therapeutics, Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~0.33). Key stats such as the average daily volume over the past year has been around 10.12 million shares, trading with heavier-than-usual volume. Headquartered in Iselin, NJ, Outlook Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Robert Charles Jahr, the company employs approximately 23 people and listed since June 14, 2016. Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications.

OTLK has shown weak momentum, losing -9.44% over the past week and -60.31% over the past quarter, though year-to-date performance is down -67.09%. Short-term trend indicators are bullishly aligned (SMA20 1.02%, SMA50 -48.54%, SMA200 -70.2%). The stock’s 14-day RSI is 38.56 (weak momentum), while the ATR of 0.06 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -87.22% below its high and over 14.0% above its low. Average 10-day trading volume of 62.94 million shares is significantly above the 3-month average of 10.49 million, indicating heightened recent market interest.

Outlook Therapeutics, Inc. trades at a P/E ratio of -0.54, slightly below the S&P 500 average, with a price-to-sales ratio of 49.36 The P/FCF stands at -0.0, also below market averages.

Outlook Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.31. This means the shares are trading above this model’s fair value.

Outlook Therapeutics, Inc. generated EPS of -$1.09 over the past year. Five-year average earnings growth is 33.18%. Wall Street analysts project EPS growth of 56.24% annually over the next five years. The latest quarter delivered EPS of -$0.16. The next quarter is forecast at -$0.17. Next year's EPS is expected at $33.33. Analyst sentiment is neutral. Analyst rating data shows there are 0 Strong Buy ratings, 3 Buy ratings, 8 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $10.00 to $0.50. The high target offers 2400.0% upside. The low target suggests 25.0% downside. The mean target is $3.77. This offers 842.5% upside. Outlook Therapeutics, Inc. earnings surprise history is a mixed track record. The quarter that ended May 15, 2026, missed forecasts by 33.33%. The prior quarter beat by 29.41%. Over the last six quarters, Apple has recorded several small beats. These include 4.71% in February 14, 2025.

Outlook Therapeutics, Inc. has 44.42 million shares outstanding. The public float is 24.35 million shares, elevated short interest at 6.71% of float. This equals 2.35 million shares. The short ratio is 2.7 days. Institutional investors hold 32.29% of the float. Insiders own 36.39%. Sukhtian Ghiath M. holds 27.83 million shares, Mohan Pankaj has 7.06 million shares and Syntone Ventures LLC has 1.07 million shares.

Our AI price prediction model suggests that Outlook Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -0.05%, with price expected at $0.40 by June 09, 2026, within a range of $0.36 to $0.45 3-Month Outlook: Projected fall of -95.0%, reaching $0.02 by August 24, 2026, with a range of $0.00 to $0.13. 1-Year Outlook: Projected loss of -82.51%, with price at $0.07 by May 26, 2027, within a range of $0.00 to $0.00.

Outlook Therapeutics, Inc. (NASDAQ:OTLK) shares are down -67.09% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Outlook Therapeutics, Inc. trading at a premium to the broader market with a P/E of -0.54. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $11.07, suggesting 2666.12% upside. Our AI forecast model points to short-term weakness (-0.05% over two weeks), a medium-term fall (-95.0% over three months), and a longer-term loss (-82.51% over one year), with expected trading ranges indicating moderate volatility.